President Donald Trump’s doctors have been treating him with different experimental drugs in hopes of alleviating his COVID-19 symptoms. He was treated with an 8-gram dose know as REGN-COV2.
The biotechnology company Regeneron calls it a cocktail of two monoclonal antibodies. Those antibodies are lab tested proteins that are made to fight infection. They are set to target against COVID-19.
Regeneron said they are using a compassionate use program as they are still in clinical trials. The antibody cocktail has not yet been approved by the US Food and Drug Administration.
Back in July, they received a $450 million contract to manufacture and supply the drug.
Doctors said the results look promising as 275 participants have already shown their treatments to be safe and relieve symptoms.
After four days of being treated for COVID-19 at Walter Reed Medical Center, President Donald Trump took to Twitter on Monday to announce his departure.
“I will be leaving the great Walter Reed Medical Center today at 6:30 P.M.
Regeneron said they will continue to study this type of therapy in hopes that the FDA will consider an emergency authorization of the drug.
- Biden officially secures enough electors to become president after California certifies
- Reed: Trump’s NDAA veto threat is harmful to the troops
- More COVID-19 cases confirmed in Shenendehowa CSD
- 5 more arrests made in connection to death of 12-year-old Columbia Co. girl
- 120 new COVID-19 cases announced in Schenectady Co. Dec. 4